

## 05-hiernet-weak-robust-10uM-new-data

Compiled at 2023-01-19 23:16:27 UTC

```
here::i_am(paste0(params$name, ".Rmd"), uuid = "e1af8f1a-2477-40d6-8300-c9019db89425")
knitr::opts_chunk$set(dpi = 200, echo = T, warning = F)
```

We use hiernet -a Lasso for (weak) hierarchical interactions- with CPSS to robustly recover interaction effects between compounds on cell morphology features. In addition we add a Huber loss to the optimization problem to account for outlier in the data. We only focus on experiments with a concentration of 10 uM per compound and use the updated data in this analysis.

### Read data

#### Input data X

```
dim(X)
```

```
## [1] 443 21
```


```
X[1:5, 1:5]
```

```
##          AMG900 Aloxistatin Berberine CA-074 Me Calcitriol
## 1-C03         0           0         0         0           0
## 1-C04         0           0         0         0           0
## 1-C05         0           1         0         0           0
## 1-C06         0           0         0         0           0
## 1-C07         0           0         0         0           0
```

```
colnames(X)[which(colnames(X) == "DMSO")] <- "1% DMSO"
```

#### Plot Design matrix X

```
pheatmap(X, cluster_rows = T, cluster_cols = F, color = c("white", "grey"),
          fontsize_row = 0.001)
```



## Remove DMSO

```
# First, remove all rows (experiments) containing DMSO in X as well as in Y
```

```
# check if rows are ordered in the same way in X and Y
```

```
all(rownames(X) == rownames(Y))
```

```
## [1] TRUE
```

```
X_initital <- X
```

```
DMSO_experiments <- which(X[, "1% DMSO"] == 0)
```

```
X <- X[DMSO_experiments, ]
```

```
Y <- Y[DMSO_experiments,]
```

```
# Then remove DMSO columns (since only zeros remain)
```

```
ind_DMSO <- which(colnames(X) == "1% DMSO")
```

```
X <- X[,-ind_DMSO]
```

```
dim(X)
```

```
## [1] 408 20
```

The experimental design consists of 408 samples and 20 compounds.

## Remove all experiments with a concentration of only 5 uM

It's already only the 10uM experiments in the updated data, so there's no need to remove experiments anymore.

## Compute interactions

```
X_interactions <- cbind(X, hierNet::compute.interactions.c(X, diagonal = F))
dim(X_interactions)
```

```
## [1] 408 210
```

There are 210 interaction coefficients when considering all-pairs of interactions from 20 compounds.

## How many replicates do exist?

```
X_unique <- X[!duplicated(X),]
dim(X_unique)
```

```
## [1] 50 20
```

There are 50 different experiments.

```
## index_replicate
## 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
## 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 18 18 18 18 8 8 8 8 8 8
## 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50
## 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
```

The individual experiments were repeated 6, 8 or 18 times.

```
dim(Y)
```

```
## [1] 408 146
```

For each experiment 146 features were observed.

## Scale Features Y

We scale the features to make our model coefficients comparable.

```
Ysc = scale(Y)
```

Let's have a look at a subset of scaled Y

```
Ysc[1:5, 1:4]
```

```
##      ValidObjectCount ObjectTotalAreaCh1 ObjectAvgAreaCh1 ObjectTotalIntenCh1
## 1-C05      1.4732718      1.459982      0.09479254      1.3242847
## 1-C06      1.9157636      2.004499      0.18774959      1.7112856
## 1-C07      0.4192962      0.143315     -0.89978854      0.2762874
## 1-C08      0.9284954      0.882009      0.34920378      0.8804891
## 1-C09      2.0447311      2.148380      0.17045864      1.8024286
```

Check if replicates do differ via heatmap plots. The heatmap plots can be found in a separate document [compare\\_replicates\\_10uM\\_newData.pdf](#).

We account for outlier samples by using a robust loss. We do not exclude any experiments in advance anymore.

## Robust HierNet

In this version the design matrix X includes duplicated rows representing replicates in the experiment.

## hierNet with Huber loss


```
fit.list.weak.10uM <- hiernet.stabsel.all(X = X, Y = Ysc,  
                                         selection_probability = 0.6)
```

### Refitting

```
refit_10uM <- refit.all(X = X, Y = Ysc, fit_list_weak =  
                        fit.list.weak.10uM)  
refit_list_weak_10uM <- refit_10uM$refit_list  
coef_list_weak_10uM <- refit_10uM$coef_list
```

How good is the predictive accuracy?

### Histogram of adjusted R squared values



How often do compounds occur together in the experimental design?

70	8	40	8	0	8	0	8	8	0	8	0	0	0	0	16	16	0	16	16	AMG900
8	46	8	0	0	16	8	24	16	8	0	0	0	0	0	8	0	0	0	0	Aloxistatin
40	8	62	8	0	0	8	16	0	0	16	0	0	8	0	16	8	0	0	8	Berberine
8	0	8	66	0	8	16	0	8	0	16	0	0	8	0	16	8	0	8	0	CA-074 Me
0	0	0	0	14	0	0	0	0	8	0	0	0	0	0	0	0	0	0	0	Calcitriol
8	16	0	8	0	54	8	8	24	8	0	0	0	16	0	0	8	0	16	0	Clardribine
0	8	8	16	0	8	66	0	24	0	8	8	0	0	0	8	8	0	0	8	Cytochalasin D
8	24	16	0	0	8	0	54	8	16	0	0	0	16	0	0	0	0	0	8	Dexamethasone
8	16	0	8	0	24	24	8	70	0	8	0	0	0	0	8	24	0	16	0	Etoposide
0	8	0	0	8	8	0	16	0	38	0	0	0	16	0	0	0	0	0	8	FCCP
8	0	16	16	0	0	8	0	8	0	50	0	0	0	0	8	0	0	0	8	Fenbendazole
0	0	0	0	0	0	8	0	0	0	0	14	0	0	0	0	0	0	0	0	LY2109761
0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	0	0	LatrunculinB
0	0	8	8	0	16	0	16	0	16	0	0	0	54	0	8	8	0	8	8	Mebendazole
0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	Nicolsamide
16	8	16	16	0	0	8	0	8	0	8	0	0	8	0	54	16	0	0	0	Nicotinamide
16	0	8	8	0	8	8	0	24	0	0	0	0	8	0	16	62	0	16	8	Rotenone
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	Staurosporine
16	0	0	8	0	16	0	0	16	0	0	0	0	8	0	0	16	0	46	8	TC-S7004
16	0	8	0	0	0	8	8	0	8	8	0	0	8	0	0	8	0	8	50	Tetrandine
AMG900	Aloxistatin	Berberine	CA-074 Me	Calcitriol	Clardribine	Cytochalasin D	Dexamethasone	Etoposide	FCCP	Fenbendazole	LY2109761	LatrunculinB	Mebendazole	Nicolsamide	Nicotinamide	Rotenone	Staurosporine	TC-S7004	Tetrandine	

How often do we observe what?


	98	112	123	95	113	118	114	122	119	124	94	64	124	83	115	123	60	119	110	AMG900
3		102	109	92	103	103	104	111	105	111	82	49	111	73	103	110	56	105	103	Aloxistatin
5	17		129	103	118	121	123	131	121	131	101	69	131	82	124	130	68	123	114	Berberine
7	0	3		108	129	135	131	140	135	144	108	69	144	95	135	143	71	137	127	CA-074 Me
0	0	0	0		99	101	105	110	102	110	88	57	110	67	103	109	59	103	96	Calcitriol
13	15	0	4	0		122	118	127	122	131	96	63	131	84	124	130	62	124	117	Clardribine
0	9	1	46	0	10		123	132	129	136	100	61	136	91	127	135	64	128	123	Cytochalasin D
37	2	45	0	0	29	0		131	125	133	103	67	133	86	124	132	67	126	117	Dexamethasone
16	37	0	18	0	37	27	28		132	142	108	70	142	92	134	141	71	134	125	Etoposide
0	42	0	0	47	17	0	4	0		136	101	63	136	93	128	135	67	130	122	FCCP
14	0	55	42	0	0	34	0	113	0		110	71	146	96	137	145	72	138	129	Fenbendazole
0	0	0	0	0	0	45	0	0	0	0		65	110	73	104	109	59	102	94	LY2109761
0	0	0	0	0	0	0	0	0	0	0	0		71	43	69	71	41	67	55	LatrunculinB
0	0	52	14	0	46	0	5	0	39	0	0	0		96	137	145	72	138	129	Mebendazole
0	0	0	0	0	0	0	0	0	0	0	0	0	0		90	95	45	90	88	Nicolsamide
9	12	9	28	0	0	20	0	2	0	39	0	0	1	0		136	69	129	121	Nicotinamide
89	0	24	23	0	16	11	0	35	0	0	0	0	70	0	60		72	138	128	Rotenone
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		69	63	Staurosporine
17	0	0	5	0	0	0	0	70	0	0	0	0	64	0	0	11	0		121	TC-S7004
43	0	5	0	0	0	10	2	0	17	18	0	0	43	0	0	15	0	3		Tetrandine
AMG900	Aloxistatin	Berberine	CA-074 Me	Calcitriol	Clardribine	Cytochalasin D	Dexamethasone	Etoposide	FCCP	Fenbendazole	LY2109761	LatrunculinB	Mebendazole	Nicolsamide	Nicotinamide	Rotenone	Staurosporine	TC-S7004	Tetrandine	

We can only find combinatorial effects for compounds that got measured together in an experiment. This means that our results are biased by the experimental design. What might be of special interest are combinations of compounds that occur often in the experiments, but which do not (or almost not) show combinatorial effects in our model.

For example Clardribine and Aloxistatin

Overall this looks similar to the results in the old data.

## All features into one plot




We can't label all features here, but we get a rough idea what kind of effects are most prevalent. We see, for instance, many antagonistic effects, where two compounds do have individual positive effects on a feature, but in combination this effect is not that strong anymore (upper right quadrant, blue points). We also see this behavior into the other direction, where two individual effects are negative, but the additional combinatorial effect is positive (lower left quadrant, red points). We also see multiple competitive (or even cancelling out) effects between the compounds, where the two compounds show an opposite behavior and the additional combinatorial effect promotes one of the two behaviors.

This plot looks a bit shifted compared to the old data.

What does this figure look like if we split it into Channels?


Channel 1: Nucleus




The behavior in the Nucleus is very similar to the overall behavior.




## Channel 2: Endoplasmic reticulum




Channel 3: Nucleoli, cytoplasmic RNA



Channel 4: Golgi, plasma membrane, F-actin, cytoskeleton



## Channel 5: Mitochondria



## Specific compound combinations


Instead of looking into different channels, we can also look into this representation by taking into account specific pairs of compounds. The Figures are in a separate document (see `scatter_plt_each_combi_robust_10uM_all_newData.pdf`)

There are different categories of behavior:

1. Antagonists: In this category two compounds show similar individual effects, but in combination their effect is lowered (less strong than expected under independence of the two individual effects or even cancelled out).

In this summary I'm only focusing on combinations that affect many features.


Here's an example:



- Rotenone and Mebendazole
- Tetrandine and Mebendazole
- Tetrandine and FCCP
- Mebendazole and FCCP
- Dexamethasone and Berberine
- Rotenone and CA-074
- Cladribine and Etoposide
- Aloxistatin and Berberine

2. Cancelling out effect (weak hierarchy): In this category a compound has a specific effect on the features, but this behavior gets reduced in combination with another compound that on its own does have no (or almost no) effect.


Here's an example:



- Positive (and negative) Rotenone effect suppressed by AMG900
- Positive and negative Rotenone effect suppressed by Berberine
- Positive and negative Mebendazole effect suppressed by Berberine
- Positive and negative TC-S7004 effect suppressed by Mebendazole
- Positive Mebendazole effect suppressed by Cladribine
- Positive Rotenone effect suppressed by Cladribine
- Positive Rotenone effect suppressed by Etoposide

### 3. Amplification effect

For Mebendazole and Berberine there's another interesting behavior. Berberine on it's own doesn't show a strong effect, but it amplifies the effect of Mebendazole.



We see such an effect for:

- Mebendazole and Berberine
- Mebendazole and TC-S7004
- (also a little bit for) Rotenone and Nicotinamide

## 70 most important features

Since 146 Features are a lot, we reduce the set to 70 Features

```
## New names:
## * `` -> `...1`
```

The following heatmap shows the estimated coefficients from the model starting with linear effects on the left followed by all interaction effects that are non zero for at least one morphological feature.






In this heatmap we can see some combinations that affect multiple features of a certain channels in the same way. For instance, a positive interaction effect between Mebendazole and TC-S7004 or between Nicotinamide and Rotenone on most of the Channel 5 features and Channel 2 features.


This is still a lot. So we reduce the set of features even further.

## 21 most important features

```
## New names:
## * `` -> `...1`
```

Reduced coefficient matrix for only 21 features







Now we look again into the scatterplots, but for the reduced set with 21 features. The reduced set allows us

to include the names of the morphological features.


## Channel 1




## Channel 2




## Channel 3



## Channel 4



## Channel 5



The document scatter\_plt\_each\_combi\_robust\_10uM\_21\_newData.pdf shows the same figures but for concrete combinations of compounds. Some observations from this representation are summarized here:

- Most drug combinations affect multiple channels in a similar way

How often do we observe what for only 21 features?

		13	16	18	12	16	17	16	18	18	18	12	6	18	15	18	17	8	17	17	AMG900
0		13	14	11	13	14	12	14	14	14	9	3	14	11	14	13	5	13	14	Aloxistatin	
1	2		19	14	16	18	18	19	18	19	12	5	19	13	19	18	8	17	18	Berberine	
3	0	0		15	18	20	19	21	20	21	14	6	21	15	21	20	9	19	20	CA-074 Me	
0	0	0	0		14	14	14	15	14	15	9	3	15	10	15	14	6	13	15	Calcitriol	
2	1	0	1	0		17	16	18	18	18	11	4	18	13	18	17	7	17	18	Clardribine	
0	2	0	6	0	0		18	20	19	20	13	5	20	14	20	19	8	18	19	Cytochalasin D	
5	0	7	0	0	5	0		19	18	19	13	6	19	13	19	18	8	17	18	Dexamethasone	
1	2	0	4	0	3	5	3		20	21	14	6	21	15	21	20	9	19	20	Etoposide	
0	4	0	0	8	3	0	2	0		20	13	6	20	15	20	19	9	19	19	FCCP	
2	0	8	3	0	0	3	0	13	0		14	6	21	15	21	20	9	19	20	Fenbendazole	
0	0	0	0	0	0	7	0	0	0	0		5	14	11	14	13	7	12	13	LY2109761	
0	0	0	0	0	0	0	0	0	0	0	0		6	5	6	6	4	6	5	LatrunculinB	
0	0	10	2	0	5	0	0	0	6	0	0	0		15	21	20	9	19	20	Mebendazole	
0	0	0	0	0	0	0	0	0	0	0	0	0	0		15	14	6	14	14	Nicolsamide	
2	1	1	6	0	0	3	0	0	0	7	0	0	0	0		20	9	19	20	Nicotinamide	
8	0	1	2	0	0	1	0	0	0	0	0	0	11	0	12		9	19	19	Rotenone	
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		9	8	Staurosporine	
1	0	0	0	0	0	0	0	8	0	0	0	0	15	0	0	3	0		18	TC-S7004	
10	0	1	0	0	0	1	0	0	4	4	0	0	8	0	0	1	0	1		Tetrandine	
AMG900	Aloxistatin	Berberine	CA-074 Me	Calcitriol	Clardribine	Cytochalasin D	Dexamethasone	Etoposide	FCCP	Fenbendazole	LY2109761	LatrunculinB	Mebendazole	Nicolsamide	Nicotinamide	Rotenone	Staurosporine	TC-S7004	Tetrandine		

## Files written

These files have been written to the target directory, data/05-hiernet-weak-robust-10uM-new-data:

```
projthis::proj_dir_info(path_target())
```

```
## # A tibble: 0 x 4
## #   ... with 4 variables: path <fs::path>, type <fct>, size <fs::bytes>,
## #   modification_time <dtm>
```